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Introduction
Thrombotic thrombocytopenic purpura (TTP) is a
rare disorder characterized by thrombocytopenia,
microangiopathic haemolytic anaemia, neurological
and renal abnormalities and fever1,  with a mortality
rate, in the absence of treatment, of almost 90%. Since
such criteria do not distinguish TTP from haemolytic
uraemic syndrome (HUS), the comprehensive term
TTP-HUS is more approriate2. The standard therapy
is urgent plasma exchange (PE)1, which reduces
mortality to 10% or less3-9. Because of its dramatic
effect on short and long-term outcome, it is now
accepted that PE can be begun, in the absence of an
alternative diagnosis, even when not all of the above
criteria are fulfilled3,4,6,9,10.  The evident advantage of
early initiation of therapy along with the decreased
diagnostic threshold has resulted in a 7-fold increase
of patients treated with PE for TTP-HUS from 1981
to 199711.
The symptoms of TTP are related to the presence
of von Willebrand factor (VWF)-rich platelet thrombi
in arterioles and capillaries. VWF is a multimeric
plasma glycoprotein crucial for both platelet adhesion
and aggregation, especially at the high shear rates
present in the microvasculature. The size of VWF
multimers is physiologically regulated in vivo by a
specific metalloprotease, ADAMTS-13 (a disintegrin-
like and metalloprotease with thrombospondin type
1 repeats)12.
A severe deficiency of ADAMTS-13 (< 5% of
normal activity) may be specific for TTP13 and it has
been proposed that severe ADAMTS-13 deficiency
now defines TTP14,15.  Because ADAMTS-13
deficiency, whether idiopathic or caused by an
autoantibody, provides a possible explanation for the
effectiveness of PE (removal of the autoantibody by
apheresis; supply of ADAMTS-13 by plasma
replacement), it has been suggested that the levels of
this metalloprotease can be used to guide treatment
decisions14,16-19.  At present it is not possible to establish
the sensitivity of ADAMTS-13 deficiency for
identifying patients who may respond to PE. In seven
reports, 45% to 100% of patients with TTP were
reported to have severe deficiency of ADAMTS-13
activity19-25 while such a high rate has not been
described in those with HUS19,20,23. However, the
interpretation of these studies is limited by the absence
of explicit criteria for distinguishing patients with TTP
from patients with HUS. PE has been proven effective
even in patients without deficiency of ADAMTS-13
activity, which makes it difficult to understand how
PE is benificial2.  In conclusion, the role of ADAMTS-
13 activity in the diagnosis and treatment decisions
in patients with TTP or HUS remains unknown.
Therapy with PE should be implemented in all
patients with TTP-HUS and continued until the
resolution of signs and/or symptoms and
normalisation of laboratory tests; this can require long-
term therapy. PE has some other disadvantages: first
of all, it is not a risk-free procedure since a substantial
number of major complications have been
reported26,27. Furthermore, about 10% to 20% of TTP-
HUS patients do not respond or have only an
incomplete response2. Various different types of
immunosuppressive treatment have been proposed for
refractory patients14,29,30,32, including steroids and
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immunosuppressive or immune-modulating agents;
however, the lack of robust data does not allow proper
suggestion of such agents in the setting of acute
refractory or chronic relapsing TTP28,32. Splenectomy
has been proposed for patients with refractory or
relapsing TTP, with reported remission rates of 50–
100%29,  but relapses have occurred in a considerable
proportion of patients, most of them with severe
ADAMTS-13 deficiency2,29,33,35. It has recently been
shown that splenectomy can cause the disappearance
of antibodies, normalisation of ADAMTS-13 activity
and clinical remission in cases of refractory/relapsing
TTP associated with anti-ADAMTS-13
autoantibodies. Other authors reported a low
frequency of relapses in a large cohort of patients who
underwent splenectomy30.
Rituximab, a chimaeric monoclonal antibody
directed against the CD20 antigen present on B
lymphocytes, is used in lymphoma patients and those
with rheumatoid arthritis33. Its action relies on
clearance of the B lymphocytes responsible for
antibody production by complement-dependent
Patient 1 2 3 4
Age/gender 28 male 53 male 52 male 16 female
Relapsing/Refractory TTP Relapsing TTP # Refractory TTP Refractory TTP Refractory TTP
Neurological symptoms None Yes Yes None
Laboratory values at diagnosis
Haemoglobin g/dL 8 7.9 10.9 12.6
Platelet count x109/L 20 30 50 9
Lactate dehydrogenase U/L 1900 1500 629 2341
Creatinine mg/dL 1.14 2.5 1.3 0.71
Schistocytes ++ ++ ++ ++++
ADAMTS-13 activity^ < 5% 100% 40%* < 5%
ADAMTS-13 inhibitor¤ >120 U/mL No detectable 65 U/mL* >120 U/mL
PE volume 1 1 1 1
PE plasma Solvent/detergent Solvent/detergent Solvent/detergent Solvent/detergent
FFP (Octaplas®) FFP (Octaplas®) FFP (Octaplas®) FFP (Octaplas®)
N. of PE before R None 9 9 13
Indication for R Relapsing TTP Refractory TTP Refractory TTP Refractory TTP
Laboratory values prior to R
Haemoglobin g/dL 11.7 9 7.6 8.7
Platelet count x109/L 54 80 80 89
Lactate dehydrogenase U/L 1870 850 568 404
Creatinine mg/dL 1.1 2.3 1.2 0.8
Schistocytes ++ ++ ++ +++
Complete remission after R Yes Yes Yes Yes
Days to CR from first R infusion 14 7 30 14
Toxicity None None None None
Duration of CR 4+ months 11+ months 10+ months 3+ months
Relapse No No No No
Status at last follow-up Alive in CR Alive in CR Alive in CR  Alive in CR
ADAMTS-13 activity after R 35% NA 90% 25%
ADAMTS13 inhibitor after R No detectable NA 8 16
Legend: # Initial episode of TTP diagnosed elsewhere 39 months – achie ved complete remission (CR) with  20 plasma exchange (PE) procedures
and steroids prior to presenting in relapse;  FFP = fresh-frozen plasma; CR= complete remission; R= rituximab;  NA= not available;  NV= normal
value; ^ADAMTS-13 activity (normal value: 50-150%);  ¤ ADAMTS-13 inhibitor (normal value: <17 U/mL); lactate dehydrogenase (normal value:
240-480 U/L); * Had undergone PE prior to initial ADAMTS-13 testing .
Table I - Patients' characteristics
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cytotoxicity, antibody-dependent cellular cytotoxicity
or directly by inducing apoptosis31,33. The
understanding that ADAMTS-13 deficiency could be
antibody-mediated first provided the rationale for the
use of rituximab in TTP-HUS12,  but its reported
effectiveness even in TTP-HUS patients without
antibody-mediated ADAMTS-13 deficiency as well
as in cases of refractory/relapsing cases makes this
monoclonal antibody a very attractive therapeutic
agent33-35.  The data suggest that the drug may not
simply decrease ADAMTS-13 autoantibody
production by depleting B cells, but that it may have
additional mechanisms of action. Kameda et al.34
suggested that B-cell depletion by rituximab reduces
excessive cytokine production in patients with
secondary TTP, thus containing the level of VWF
multimers within the normal range. At present, only
data from case series have been published and many
questions remain open regarding the target population,
timing of initiation, duration of treatment and
concomitant PE34-49.  Here we describe four patients
with refractory/relapsing idiopathic TTP-HUS who
were successfully treated with rituximab (Table I).
Case reports
Case 1
In October 2005 a 28-year-old male was diagnosed
with idiopathic TTP-HUS. At presentation, the patient
had anaemia (haemoglobin 8 g/dL), an abnormal
platelet count of 20x109/L and a low-grade fever; he
did not have nausea, vomiting or any focal
neurological deficiency.  A direct antiglobulin test
(DAT) was negative; his lactate dehydrogenase (LDH)
concentration was 1900 UI/L (normal value, n.v. 240-
480), and that of the indirect bilirubin was 2.5 mg/
dL. Schistocytes, helmet forms, nucleated red blood
cells (RBC) and marked thrombocytopenia were noted
on a peripheral blood smear. ADAMTS-13 activity
was <5% (n.v. 50-150%) due to the presence of
inhibitory antibodies against ADAMTS-13 (titre >120
U/mL;  n.v. <17 U/mL). ADAMTS-13 activity was
determined by a fluorimetric method and IgG anti-
ADAMTS-13 by an enzyme-linked immunosorbent
assay (ELISA). The patient was initially treated with
daily PE and methylprednisolone i.v. 1 mg/kg/die and
achieved a complete remission after 20 sessions of
PE. At that time, ADAMTS-13 activity was 45% and
antibodies were not detectable. The complete
remission lasted for 39 months. In October 2008 the
patient relapsed, and ADAMTS-13 activity was 20%.
Rituximab was initiated, given as a single agent once
a week for 4 weeks, at a dose of 375 mg/m2 for each
single infusion (Figure 1). Laboratory values
normalised after the first two infusions (platelet count
increased to 133 x 109/L and LDH decreased to 455
UI/L) and antibodies against ADAMTS-13 were not
detectable; ADAMTS-13 activity was 35%. At the
present, the patient is in complete remission.
Figure 1 - Changes in LDH and platelet count during
treatment and in the follow-up period (October
2005- February 2009) for patient n. 1
Case 2
In March 2008 a 53-year-old male with suspected
TTP-HUS was admitted to our division because of
the onset of behavioural changes, fainting, loss of
bladder sphincter control, anaemia and
thrombocytopenia. His platelet count was 30x109/L
and haemoglobin concentration 7.9 g/dL; LDH was
increased to 1500 UI/L and serum creatinine was 2.5
mg/dL. The patient's coagulation profile was normal.
A peripheral blood smear showed 2+ schistocytes and
the DAT was negative. ADAMTS-13 activity was
100% and antibodies against ADAMTS-13 were not
detectable. ADAMTS-13 activity was determined by
fluorimetry and IgG anti-ADAMTS-13 by ELISA.
PE and methylprednisolone i.v 1 mg/Kg/die were
initiated promptly. Because the response was only
partial (platelets: 80x109/L) after nine sessions of PE,
we started, in accordance with current literature33-
51,54,55
, treatment with rituximab (at a standard dosage
of 375mg/m2 once a week for 4 weeks) while the
methylprednisolone therapy was reduced (from 1 mg/
Rituximab for managing relapsing/refractory patients with idiopathic TTP-HUS
Legend: PE: Plasma exchange; (n): number of daily plasma exchange
procedures or days of MP therapy; MP: methylprednisolone.
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kg during the first week to 0.5 mg/kg during the
second week). Laboratory values recovered quickly
after the first dose of rituximab and remained stable
during all the courses of the therapy. After a follow-
up of 11 months, the patient has achieved a complete
remission (Figure 2).
Figure 3 - Changes in LDH and platelet count during
rituximab treatment and during the follow-up
period (April 2008 – February 2009) for
patient n. 3
Figure 2 - Changes in LDH and platelet count during
rituximab treatment and in the follow-up period
(March 2008- February 2009) for patient n. 2
Case 3
In April 2008 a 52-year-old male was admitted
to an intensive care ward for dizziness, bilious
vomiting, anaemia and thrombocytopenia. He was
diagnosed as having idiopathic TTP-HUS and PE
and methylprednisolone 1mg/kg/die were initiated
promptly. ADAMTS-13 activity was assayed after
only six PE procedures and found to be 40%; the
anti-ADAMTS-13 antibody (IgG) titre was 65 U/
mL. As for the other cases, ADAMTS13 activity
was determined by a fluorimetric method and IgG
anti-ADAMTS-13 by ELISA. PE was continued up
to nine procedures; however, although there was
modest recovery of platelet count from 50 x 109/L
to 80 x 109/L, the presence of anaemia
(haemoglobin, 7.6 g/dL), still high LDH (568 UI/
L) and 2+ schistocytes on a peripheral blood smear
led us to consider the patient as refractory to PE
treatment. Therapy with rituximab (4 weekly doses
of 375mg/m2) was, therefore, started. ADAMTS-
13 activity increased promptly to 90% and the IgG
anti-ADAMTS-13 titre decreased to 8 U/mL after
the fourth infusion of rituximab. After a follow-up
of 10 months, the patient is clinically stable and in
complete remission (Figure 3).
Case 4
In November 2008 a 16-year-old female was
admitted to our Division of Haematology because of
jaundice, severe thrombocytopenia and increased
LDH. Her platelet count was 9x109/L, haemoglobin
12.6 g/dL, LDH 2341 UI/L and serum indirect
bilirubin 16.6 mg/dL; the fibrinogen concentration and
coagulation profile were normal. A peripheral blood
smear showed 4+ schistocytes; the DAT was negative.
ADAMTS-13 activity was <5% because of the
presence of specific antibodies (titre, >120 U/mL).
The patient was diagnosed as having idiopathic TTP-
HUS and was initially treated with PE and
methylprednisolone i.v. 1 mg/kg/die for 13 days. The
patient did not recover completely (platelet count 89
x 109/L, hemoglobin 8.7 g/dL, LDH  404 UI/L) and
she was considered refractory to PE treatment.
Rituximab was initiated at the standard dose (Figure
4). Laboratory values normalised after two rituximab
infusions and ADAMTS-13 activity increased to 25%.
Three months after the end of therapy the patient is in
complete remission.
Discussion
Idiopathic TTP/HUS is a life-threatening disease
that is still difficult to manage properly. The current
standard therapy is PE performed daily until resolution
of symptoms and/or normalisation of laboratory
values (recovery of platelet count, increase of
haemoglobin, decrease of LDH and absence of
Blood Transfus 2010;8:203-10  DOI 10.2450/2009.0101-09
Legend: PE: Plasma exchange; (n): number of daily plasma exchange
procedures or days of MP therapy; MP: methylprednisolone.
Legend: PE: Plasma exchange; (n): number of daily plasma exchange
procedures or days of MP therapy; MP: methylprednisolone.
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The discovery that deficiency of ADAMTS-13
may be related to the severity and prognosis of
idiopathic TTP-HUS has raised many questions about
the need to test this marker at diagnosis and/or during
remission with the aim of identifying patients at high
risk of recurrent TTP/HUS15-18. Some uncertainties
remain since ADAMTS-13 deficiency is not detected
in all patients who may be appropriately diagnosed
as having TTP-HUS2,34,35. At present, there are
insufficient data to manage TTP patients safely based
on levels of ADAMTS-13.
PE may be an effective treatment for TTP
because of clearance of antibodies against ADAMTS-
13, but it poorly effective in cases of secondary TTP.
Consequently, it has been postulated that PE may not
be effective in patients without ADAMTS-13
deficiency, but some reports have been proven that it
can be2,33,34.  For these reasons, PE remains the standard
treatment for idiopathic TTP-HUS independently of
the detection of ADAMTS-13 antibodies2.
Despite the considerable improvement in survival
associated with prompt initiation of daily PE in
patients with idiopathic TTP-HUS,  some patients
have an incomplete or delayed response or do not
respond at all to this standard treatment2,10-33,51. About
10% to 20% of TTP-HUS patients are refractory (even
after several procedures) or relapse a few years after
treatment46. Although there is no generally accepted
definition of refractory disease, escalation of therapy
should be considered after 7 to 14 days of treatment
with daily PE and steroids, when the clinical picture
deteriorates or laboratory findings do not improve2,52,53.
In these cases, additional therapy with
immunosuppressive drugs (such as steroids,
cyclophosphamide or cyclosporine) has not been
proven to be beneficial in all investigations14,29,30.
There is increasing evidence that rituximab has a
role to play in the treatment of acute refractory/
relapsing idiopathic TTP/HUS, particularly in those
cases in which ADAMTS-13 inhibitory antibodies are
present36-49,56.  In our experience, three out of four
patients with severe, antibody-mediated deficiency of
ADAMTS-13 had a complete remission after
treatment with rituximab. We, and others34,35, found
that this drug was effective even in a patient with
refractory TTP-HUS without ADAMTS-13
deficiency. The mechanism of action of rituximab in
such patients is unclear. Kameda et al. suggested that
B-cell depletion by the anti-CD20 monoclonal
antibody may reduce excessive cytokine production
in patients with secondary TTP and thus contain the
level of VWF multimers within the normal range33,34.
This mechanism may also explain the success of PE
in patients without ADAMT-13 deficiency or in those
with secondary TTP-HUS.
All our patients achieved clinical remission and
normalisation of laboratory values after a few
infusions of rituximab without experiencing any
adverse reaction. The median follow-up was 7 months
(range, 3 to 11); this is similar to the follow-up in
previous reports34-49.
Our results and those of others suggest that
rituximab could be a useful treatment in TTP patients
but there is still a lack of reliable data on the optimal
time schedule and dose, duration of therapy, long-
term maintenance of remission and side effects in
patients with acute refractory and relapsing TTP. When
determining the role of rituximab in this setting, the
risks and benefits of different treatments must be
balanced. PE is expensive and often associated with
complications related to venous access lines, including
infection, catheter thrombosis, hypoxaemia,
hypotension and transfusion reactions50.  Rituximab
induces rapid remissions in a high proportion of
patients with acute refractory TTP treated early after
7-14 PE sessions and seems to have few side
effects33,45.  Clinical trials are now ongoing and will
probably provide answers to some of the most debated
Figure 4 - Changes in LDH and platelet count during
treatment with rituximab and in the follow-up
period (November 2008-February 2009) for
patient n. 4
Rituximab for managing relapsing/refractory patients with idiopathic TTP-HUS
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Legend: PE: Plasma exchange; (n): number of daily plasma exchange
procedures or days of MP therapy; MP: methylprednisolone.
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questions about the clinical use of ADAMTS-13
measurements as well as the appropriate setting for
therapy with rituximab. In the meantime, the use of
rituximab fairly early (within 7–14 days) in patients
with  refractory/relapsing TTP-HUS can be beneficial.
Although the optimal dose of rituximab in this setting
has not been defined, the standard treatment of 375
mg/m2 once weekly for 4 weeks seems appropriate.
The effectiveness of different schedules of therapy,
such as only one or two doses of 375 mg/m2 or a
reduction of each dose administered, needs further
study.
In conclusion, rituximab has a role to play in the
treatment of patients with a first episode of acute
refractory autoantibody-induced TTP/HUS. Induction
of remission by rituximab is associated with the
disappearance of ADAMTS-13 inhibitors and
normalisation of ADAMTS-13 activity. Rituximab
may also be effective for treating patients with
relapsed/refractory TTP-HUS without ADAMTS-13
deficiency. In our opinion and based on the available
data, rituximab may be a therapeutic option in patients
with idiopathic TTP-HUS, with or without ADAMTS-
13 deficiency, who fail to respond after 7–14 days of
standard treatment.
References
1) Amorosi EL, Ultmann JE. Thrombotic
thrombocytopenic purpura: report of 16 cases and
review of the literature. Medicine 1966; 45: 139-59.
2) Vesely SK, George JN, Lämmle B, et al. ADAMTS13
activity in thrombotic thrombocytopenic purpura-
hemolytic syndrome: relation to presenting features and
clinical outcomes in a prospective cohort of 142 patients.
Blood 2003; 102: 60-8.
3) Rock GA, Shumak KH, Buskard NA, et al. Comparison
of plasma exchange with plasma infusion in the
treatment of thrombotic thrombocytopenic purpura. N
Engl J Med 1991; 325: 393-7.
4) Rock G, Shumak K, Kelton J, et al. Thrombotic
thrombocytopenic purpura: outcome in 24 patients with
renal impairment treated with plasma exchange.
Transfusion 1992; 32: 710-4.
5) Bell WR, Braine HG, Ness PM, Kickler TS. Improved
survival in thrombotic thrombocytopenic purpura-
hemolytic uremic syndrome. N Engl J Med 1991; 325:
398-403.
6) Thompson CE, Damon LE, Ries CA, Linker CA.
Thrombotic microangiopathies in the 1980s: clinical
features, response to treatment, and the impact of the
human immunodeficiency virus epidemic. Blood 1992;
80: 1890-5.
7) Hayward CPM, Sutton DMC, Carter WH Jr, et al.
Treatment outcomes in patients with adult thrombotic
thrombocytopenic purpura-hemolytic uremic syndrome.
Arch Intern Med 1994; 154: 982-7.
8) Elkins SL, Wilson PP, Files JC, Morrison FS.
Thrombotic thrombocytopenic purpura: evolution
across 15 years. J Clin Apheresis 1996; 11: 173-5.
9) Lara PN Jr, Coe TL, Zhou H, et al. Improved survival
with plasma exchange in patients with thrombotic
thrombocytopenic purpura-hemolytic uremic syndrome.
Am J Med 1999; 107: 573-9.
10) George JN. How I treat patients with thrombotic
thrombocytopenic purpura-hemolytic uremic syndrome.
Blood 2000; 96: 1223-9.
11) Clark WF, Rock GA, Buskard N, et al. Therapeutic
plasma exchange: an update from the Canadian
Apheresis Group. Ann Int Med 1999; 131: 453-62.
12)  Fankouri F, Vernant JP, Veyradier A, et al. Efficiency
of curative and prophylactic treatment with rituximab
in ADAMTS13 deficient thrombotic thrombocytopenic
purpura: a study of 11 cases. Blood 2005; 106: 1932-7.
13) Bianchi V, Robles R, Alberio L, et al. Von Willebrand
factor-cleaving protease (ADAMTS13) in
thrombocytopenic disorders: a severely deficient activity
is specific for thrombotic thrombocytopenic purpura.
Blood 2002; 100: 710-3.
14) Moake JL. Thrombotic microangiopathies. N Engl J
Med 2002; 347: 589-600.
15) Tsai H-M. Deficiency of ADAMTS13 and thrombotic
thrombocytopenic purpura. Blood 2002; 100: 3839-40.
16) Mannucci PM. Thrombotic thrombocytopenic purpura:
a simpler diagnosis at last? Thromb Haemost 1999; 82:
1380-1.
17) Cines DB, Konkle BA, Furlan M. Thrombotic
thrombocytopenic purpura: a paradigm shift? Thromb
Haemost 2000; 84: 528-35.
18) Lankford KV, Hillyer CD. Thrombotic
thrombocytopenic purpura: new insights in disease
pathogenesis and therapy. Transfus Med Rev 2000; 14:
244-57.
19) Mori Y, Wada H, Gabazza EC, et al. Predicting response
to plasma exchange in patients with thrombotic
thrombocytopenic purpura with measurement of vWF-
cleaving protease activity. Transfusion 2002; 42: 572-
80.
20) Furlan M, Robles R, Galbusera M, et al. Von Willebrand
factor-cleaving protease in thrombotic
thrombocytopenic purpura and the haemolytic uremic
syndrome. N Engl J Med 1998; 339: 1578-84.
21) Tsai H-M, Lian ECY. Antibodies to von-Willebrand
Blood Transfus 2010;8:203-10  DOI 10.2450/2009.0101-09
209
factor-cleaving protease in acute thrombotic
thrombocytopenic purpura. N Engl J Med 1998; 339:
1585-94.
22) Moore JC, Hayward CPM, Warkentin TE, Kelton. JG.
Decreased von Willebrand factor protease activity
associated with thrombocytopenic disorders. Blood
2001; 98: 1842-6.
23) Veyradier A, Obert B, Houllier A, et al. Specific von
Willebrand factor-cleaving protease in thrombotic
microangiopathies: a study of 111 cases. Blood 2001;
98: 1765-72.
24) Raife TJ, Lentz SR, Atkinson BS, et al. Factor  V Leiden:
a genetic risk factor for thrombotic microangiopathy in
patients with normal von Willebrand factor-cleaving
protease activity. Blood 2002; 99: 437-42.
25) Rick ME, Moll S, Taylor MA, et al. Clinical use of a
rapid collagen-binding assay for von Willebrand factor
cleaving protease in patients with thrombotic
thrombocytopenic purpura. Thromb Haemost 2002; 88:
598-604.
26) Rizvi MA, Vesely SK, George JN, et al. Complications
of plasma exchange in 71 consecutive patients treated
for clinically suspected thrombotic thrombocytopenic
purpura-hemolytic uremic syndrome. Transfusion 2000;
40: 896-901.
27) McMinn JR, Thomas IA, Terrell DR, et al.
Complications of plasma exchange in patients treated
for clinically suspected thrombotic thrombocytopenic
purpura-hemolytic uremic syndrome: an additional
study of 78 consecutive patients. Transfusion 2003; 43:
415-6.
28) Allford SL, Hunt BJ, Rose P, Machin S. Guidelines on
the diagnosis and management of the thrombotic
microangiopathic haemolytic anemia. Br J Haematol
2003; 120: 556-73.
29) Sadler JE, Moake JL, Miyata T, George JN. Recent
advances in thrombotic thrombocytopenic purpura.
Hematology 2004. Washington DC: American Society
of Hematology; 2004. p. 407-23.
30) Kappers-Klunne MC, Wijermans P, Fijnheer R, et al.
Splenectomy for the treatment of thrombotic
thrombocytopenic purpura. Br J Haematol 2005; 130:
768-76.
31) Arnold DM, Dentali F, Crowther MA, et al. Systematic
review: efficacy and safety of rituximab for adults with
idiopathic thrombocytopenic purpura. Ann Intern Med
2007; 146: 25-33.
32) Quintini G, Barbera V, Iannitto E, Mariani G. Potential
strategies for the treatment of plasma exchange-resistant
thrombotic thrombocytopenic purpura. Br J Haematol
2001; 113: 560-2.
33) Garvey B. Rituximab in the treatment of autoimmune
haematological disorders. Br J Haematol Rev 2008; 141:
149-69.
34) Kameda T, Dobashi H, Kittaka K, et al. Two cases of
refractory thrombotic thrombocytopenic purpura
associated with collagen vascular disease were
significantly improved by rituximab treatment. Clin
Rheumatol 2007 ; 26: 2159-62.
35) Reddy PS, Deauna-Limayo D, Cook JD, et al.
Rituximab in the treatment of relapsed thrombotic
thrombocytopenic purpura. Ann Hematol  2005 ; 84:
232-5.
36) Yomtovian R, Niklinski W, Silver B, et al. Rituximab
for chronic recurring thrombotic thrombocytopenic
purpura: a case report and review of the literature. Br J
Haematol 2004; 124: 787–95.
37)  Chemnitz J, Draube A, Scheid C, et al. Successful
treatment of severe thrombotic thrombocytopenic
purpura with the monoclonal antibody rituximab. Am J
Hematol 2002; 71: 105-8.
38)  Sallah S, Husain A, Wan JY, Nguyen NP. Rituximab in
patients with refractory thrombotic thrombocytopenic
purpura. J Thromb Haemost 2004; 2: 834-6.
39) Ahmad A, Aggarwal A, Sharma D, et al. Rituximab for
treatment of refractory/relapsing thrombotic
thrombocytopenic purpura (TTP). Am J Hematol 2004;
77: 171-6.
40) Koulova L, Alexandrescu D, Dutcher JP, et al.
Rituximab for the treatment of refractory idiopathic
thrombocytopenic purpura (ITP) and thrombotic
thrombocytopenic purpura (TTP): report of three cases.
Am J Hematol 2005; 78: 49-54.
41) Millward PM, Bandarenko N, Chang PP, et al.
Cardiogenic shock complicates successful treatment of
refractory thrombotic thrombocytopenic purpura with
rituximab. Transfusion 2005; 45: 1481-6.
42) Scott SM, Szczepieorkowski ZM. Rituximab for TTP.
Am J Hematol 2005; 80: 878.
43) Yassa SK, Blessios G, Marinides G, Venuto RC. Anti-
CD20 monoclonal antibody (Rituximab) for life-
threatening hemolytic–uremic syndrome. Clin
Transplant 2005; 19: 423–6.
44) Daraibi K, Berg AH. Rituximab can be combined with
daily plasma exchange to achieve effective B-cell
depletion and clinical improvement in acute
autoimmune TTP. Am J Clin Pathol 2006; 125: 592-7.
45) Scully M, Cohen H, Cavenagh J, et al. Remission in
acute refractory and relapsing thrombotic
thrombocytopenic purpura following rituximab is
associated with a reduction in IgG antibodies to
ADAMTS-13. Br J Haematol 2006; 136: 451-61.
46) Rüfer A, Brodmann D, Gregor M, et al. Rituximab for
acute plasma-refractory thrombotic thrombocytopenic
Rituximab for managing relapsing/refractory patients with idiopathic TTP-HUS
Blood Transfus 2010;8:203-10  DOI 10.2450/2009.0101-09
210
purpura. A case report and concise review of the
literature. Swiss Med Wkly 2007; 137: 518-24.
47) Chow KV, Carroll R, Branley P, et al. Anti-CD20
antibody in thrombotic thrombocytopenic purpura
refractory to plasma exchange. Intern Med J 2007;
37: 329-32.
48) Jasti S, Coyle T, Gentile T, et al. Rituximab as an adjunct
to plasma exchange in TTP: a report of 12 cases and
review of literature. J Clin Apher 2008; 23: 151-6 .
49) Arici B, Trendelenburg M. Successful treatment of
thrombotic thrombocytopenic purpura (TTP) with
rituximab. Ther Umsch 2008; 65: 710-2.
50) Lalmuanpuii J, Yalamanchili K, Fircanis S, Nelson JC.
Hypersensitivity to plasma exchange in a patient with
thrombotic thrombocytopenic purpura. J Clin Apher
2009; 24: 18-20.
51) Bresin E, Gastoldi S, Daina E, et al. Rituximab as pre-
emptive treatment in patients with thrombotic
thrombocytopenic purpura and evidence of anti-
ADAMTS13 autoantibodies. Thromb Haemost 2009;
101: 233-8.
52) Pereira A, Mazzara R, Monteagudo J, et al. Thrombotic
thrombocytopenic purpura/hemolytic uremic syndrome:
a multivariate analysis of factors predicting the response
to plasma exchange. Ann Hematol 1995; 70: 319–23.
Received: 14 April 2009 - Revision accepted: 6 August 2009
Correspondence: Sergio Siragusa, MD
Cattedra ed U.O. di Ematologia con trapianto
Azienda Ospedaliera Universitaria Policlinico “Paolo Giaccone” di Palermo
Via del Vespro 127, I-90127 Palermo, Italy
e-mail: sergio.siragusa@unipa.it
53) Guidelines for the use of fresh-frozen plasma,
cryoprecipitate and cryosupernatant. British Committee
for Standards in Haematology, Blood Transfusion Task
Force. Br J Haematol 2004; 126: 11–28.
54) Sadler JE. Von Willebrand factor, ADAMTS13, and
thrombotic thrombocytopenic purpura. Blood 2008;
112: 11-8.
55) Mannucci PM, Lavoretano S, Peyvandi F. The
thrombotic microangiopathies. Blood Transfus 2005;
3: 120-35.
56) Franchini M, Veneri D, Lippi G, Stenner R. The efficacy
of rituximab in the treatment of inhibitor-associated
hemostatic disorders. Thromb Haemost 2006;
96: 119-25.
Blood Transfus 2010;8:203-10  DOI 10.2450/2009.0101-09
Caramazza D et al
